Form 4: Janux Therapeutics CEO Reports Stock Transaction
Insider Transaction (Form 4)
David Alan Campbell, President and CEO and a Director of Janux Therapeutics, Inc., reported a transaction in 123,840 shares of common stock on July 31, 2026.
Summary
- Bona fide gift: disposed of 123,840 Common Stock on July 31, 2026; holds 264,742 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
David Alan Campbell — Director, Officer (President and CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-31 | Bona fide gift | Common Stock | 123,840 | — | — | 264,742 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-31 | Bona fide gift (123,840 shares) |
Keywords
insider transaction, Form 4, JANX, Janux Therapeutics, Inc., neutral, David Alan Campbell
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.